Ongoing Clinical Trial at the Cancer Immunology and Immunotherapy Center (CIIC)

Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2- Node-Positive and High-Risk Node-Negative Breast Cancer Patients to Prevent Recurrence (read brochure in greek)

Protocol ID Code: CP-BR-1-2007
National Organization for Medicines ID Code: IS 52/01-03-07
EudraCT Number:  2007-000934-38
ClinicalTrials.gov Identifier:  NCT00524277

Closed Clinical Trials at the Cancer Immunology and Immunotherapy Center (CIIC)

Active Immunization (Vaccination) of Patients with Prostate Cancer with a HER-2/neu Synthetic Peptide
A Phase I clinical trial on a novel immunotherapeutic vaccine, AE37, was conducted in collaboration with the Urology Clinic of  Saint Savas Hospital.  The AE37 vaccine is a synthetic HER-2/neu oncogene peptide developed by Antigen Express, Inc. The peptide is designed to stimulate an immune response against tumors expressing the oncoprotein.
The prostate cancer vaccination trial involved 30 patients, monitoring safety and immunological responsiveness to a dose of the vaccine previously shown to be well tolerated in breast cancer patients.

Protocol ID Code: GENEREX-06-07
National Organization for Medicines ID Code: IS107/2006
EudraCT Number:  2006-003299-37

Adoptive Transfer of Activated Natural Killer Cells for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer
A phase I clinical trial, monitoring safety and possible therapeutic potential of the administration of allogenic, ex vivo expanded NK cells in patients with advanced non-small cell lung cancer (NSLC).  Two to four doses of NK cells by intravenous injection in conjuction with conventional chemotherapy were administered to 16 recipients.  NK cells originated from close family members were activated and cultured in the presence of IL15 and hydrocortisone.

Protocol ID Code: PEP-CP-08-05
National Organization for Medicines ID Code: IS 89/2006
EudraCT Number:  2005-005125-58